Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties.
Xiao D, Zhu X, Yu Y, Shao N, Wu J, McCormick KD, Dhondi P, Qin J, Mazzola R, Tang H, Rao A, Siliphaivanh P, Qiu H, Yang X, Rivelli M, Garlisi CG, Eckel S, Mukhopadhyay G, Correll C, Rindgen D, Aslanian R, Palani A. Xiao D, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1615-20. doi: 10.1016/j.bmcl.2014.01.043. Epub 2014 Feb 2. Bioorg Med Chem Lett. 2014. PMID: 24556380
Spiro-piperidine azetidinones as potent TRPV1 antagonists.
Xiao D, Palani A, Aslanian R, McKittrick BA, McPhail AT, Correll CC, Phelps PT, Anthes JC, Rindgen D. Xiao D, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2009 Feb 1;19(3):783-7. doi: 10.1016/j.bmcl.2008.12.024. Epub 2008 Dec 10. Bioorg Med Chem Lett. 2009. PMID: 19114307
Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma.
Huang X, Brubaker J, Zhou W, Biju PJ, Xiao L, Shao N, Huang Y, Dong L, Liu Z, Bitar R, Buevich A, Jung J, Peterson SL, Butcher JW, Close J, Martinez M, MacCoss RN, Zhang H, Crawford S, McCormick KD, Aslanian R, Nargund R, Correll C, Gervais F, Qiu H, Yang X, Garlisi C, Rindgen D, Maloney KM, Siliphaivanh P, Palani A. Huang X, et al. Among authors: rindgen d. ACS Med Chem Lett. 2018 Jun 23;9(7):679-684. doi: 10.1021/acsmedchemlett.8b00145. eCollection 2018 Jul 12. ACS Med Chem Lett. 2018. PMID: 30034600 Free PMC article.
3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P, Taveras A, Yu Y, Zheng J, Chao J, Rindgen D, Jakway J, Hipkin RW, Fossetta J, Fan X, Fine J, Qiu H, Merritt JR, Baldwin JJ. Biju P, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2008 Jan 1;18(1):228-31. doi: 10.1016/j.bmcl.2007.10.094. Epub 2007 Oct 30. Bioorg Med Chem Lett. 2008. PMID: 18006311
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y, Dwyer MP, Chao J, Aki C, Chao J, Purakkattle B, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Qiu H, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, He Z, Lai G, Wu M, Taveras A. Yu Y, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1318-22. doi: 10.1016/j.bmcl.2008.01.024. Epub 2008 Jan 11. Bioorg Med Chem Lett. 2008. PMID: 18242983
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C, Chao J, Ferreira JA, Dwyer MP, Yu Y, Chao J, Merritt RJ, Lai G, Wu M, Hipkin RW, Fan X, Gonsiorek W, Fosseta J, Rindgen D, Fine J, Lundell D, Taveras AG, Biju P. Aki C, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4446-9. doi: 10.1016/j.bmcl.2009.05.049. Epub 2009 May 18. Bioorg Med Chem Lett. 2009. PMID: 19525110
Generation of Leads for γ-Secretase Modulation.
Mandal M, Buevich A, Caldwell JP, Hyde L, Huang X, Liu X, McKittrick B, Mazzola RD, Pissarnitski D, Palani A, Zhang L, Parker E, Xiao L, Rindgen D, Zhu Z. Mandal M, et al. Among authors: rindgen d. J Med Chem. 2020 Aug 13;63(15):8216-8230. doi: 10.1021/acs.jmedchem.0c00446. Epub 2020 Aug 4. J Med Chem. 2020. PMID: 32786237
C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J, Taveras AG, Chao J, Aki C, Dwyer M, Yu Y, Purakkattle B, Rindgen D, Jakway J, Hipkin W, Fosetta J, Fan X, Lundell D, Fine J, Minnicozzi M, Phillips J, Merritt JR. Chao J, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3778-83. doi: 10.1016/j.bmcl.2007.04.016. Epub 2007 Apr 10. Bioorg Med Chem Lett. 2007. PMID: 17459706
T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.
Smith EM, Sorota S, Kim HM, McKittrick BA, Nechuta TL, Bennett C, Knutson C, Burnett DA, Kieselgof J, Tan Z, Rindgen D, Bridal T, Zhou X, Jia YP, Dong Z, Mullins D, Zhang X, Priestley T, Correll CC, Tulshian D, Czarniecki M, Greenlee WJ. Smith EM, et al. Among authors: rindgen d. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4602-6. doi: 10.1016/j.bmcl.2010.06.012. Epub 2010 Jun 8. Bioorg Med Chem Lett. 2010. PMID: 20580233
Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.
Mandal M, Tan Z, Madsen-Duggan C, Buevich AV, Caldwell JP, Dejesus R, Flattery A, Garlisi CG, Gill C, Ha SN, Ho G, Koseoglu S, Labroli M, Basu K, Lee SH, Liang L, Liu J, Mayhood T, McGuinness D, McLaren DG, Wen X, Parmee E, Rindgen D, Roemer T, Sheth P, Tawa P, Tata J, Yang C, Yang SW, Xiao L, Wang H, Tan C, Tang H, Walsh P, Walsh E, Wu J, Su J. Mandal M, et al. Among authors: rindgen d. J Med Chem. 2017 May 11;60(9):3851-3865. doi: 10.1021/acs.jmedchem.7b00113. Epub 2017 Mar 29. J Med Chem. 2017. PMID: 28322556
33 results